Retatrutide Explained: Triple Agonist Peptide (GLP-1/GIP/Glucagon) Science

By Sam Smith

When Eli Lilly published the Phase 2 retatrutide obesity trial in the New England Journal of Medicine in July 2023, the headline number stopped a lot of people: 24.2% average body weight reduction at the 12 mg dose over 48 weeks. For context, that's more weight loss than bariatric surgery produces in many trials — and it came from a once-weekly injection. The compound, LY3437943, is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Adding glucagon receptor agonism to the dual incretin profile of tirzepatide was the key design decision, and it's that third receptor that appears to drive the energy expenditure component responsible for the compound's outsized efficacy.

Here's the thing about glucagon receptor agonism: it has historically been considered a liability in metabolic drug design, not an asset. Glucagon raises blood glucose — that's its primary function. Layering it onto an antidiabetic compound seems counterintuitive. The resolution is that at the doses and ratios used in retatrutide, the GLP-1 and GIP components maintain glycemic control while the glucagon component drives thermogenesis and fat oxidation through hepatic and adipose pathways. The net effect is additive on weight loss without the glycemic cost you'd predict from glucagon agonism in isolation. Whether that balance can be maintained across the broader population is one of the central questions the Phase 3 TRIUMPH program is designed to answer.

This guide covers how retatrutide's triple-receptor mechanism compares with semaglutide and tirzepatide, what the Phase 2 trial data shows on weight reduction, liver fat, glycemic control, and adverse events, the Phase 3 program timeline, and what researchers need to know about the compound's current development status. Every claim links to primary sources.

What does retatrutide do and how does it work?

Retatrutide is a 39-amino-acid synthetic peptide receptor agonist engineered to bind and activate three incretin-class receptors at once: GLP-1, GIP, and glucagon. According to the original PubMed-indexed pharmacology paper from Eli Lilly, LY3437943 is a novel triple agonist peptide at the glucagon receptor, GIP, and GLP-1 with balanced potencies designed to combine the appetite-suppressive effects of GLP-1, the insulinotropic effects of GIP, and the energy-expenditure-raising effects of glucagon receptor activation.

The triple agonism is the key design choice. GLP-1 alone produces appetite suppression and weight loss. GLP-1 + GIP (tirzepatide) adds adipocyte and central nervous system effects that push weight loss further. Adding glucagon receptor (GCGR) agonism adds an active energy-expenditure component. Published research shows that GCGR agonism increases energy expenditure to a magnitude sufficient for inducing a negative energy balance even without further appetite suppression, providing the third pillar of the triple-agonist effect.

The peptide also incorporates N-terminal modifications that protect against degradation. Published research shows that N-terminal modification of GLP-1 confers resistance to dipeptidyl peptidase IV degradation, which is the basis for the once-weekly subcutaneous dosing that retatrutide and other incretin therapies use.

How much weight loss does retatrutide produce?

The Phase 2 obesity dataset is the strongest evidence for retatrutide effect sizes. According to the PubMed-indexed Phase 2 obesity trial paper, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight: 8.7 percent at 1 mg, 17.1 percent at 4 mg, 22.8 percent at 8 mg, and 24.2 percent at the 12 mg dose, all once-weekly subcutaneous. The 12 mg cohort showed roughly 100 percent of participants achieving at least 5 percent body weight reduction over the 48 weeks.

For context, semaglutide’s STEP-1 trial reported 14.9 percent average weight loss over 68 weeks; tirzepatide’s SURMOUNT-1 reported 20.9 percent at the top dose over 72 weeks. Retatrutide hit 24.2 percent in a shorter 48-week window, suggesting the triple-agonist mechanism may push the ceiling of pharmacological weight loss higher than the dual-agonist class.

Hepatic fat and metabolic measures

Beyond body weight reduction, retatrutide showed strong hepatic-steatosis effects. Published research shows that LF reductions were significantly related to changes in body weight, abdominal fat and metabolic measures, with liver fat content dropping by 80 to 90 percent in patients with baseline NAFLD over 48 weeks of treatment. Glycemic control, blood pressure, and triglyceride markers improved in parallel.

The hepatic effect is particularly notable because the glucagon agonism component theoretically raises hepatic glucose production, which would counteract some of the diabetes benefit. In practice, the GLP-1 and GIP components dominate the net metabolic balance, and glycemic control improves rather than worsens with retatrutide treatment.

Is retatrutide better than Ozempic?

On the weight loss endpoint, the indirect-comparison evidence places retatrutide ahead. Average weight loss of 24.2 percent at 12 mg (retatrutide, 48 weeks) versus 14.9 percent at 2.4 mg (semaglutide, 68 weeks) is a substantial margin. The class differences:

• Ozempic/Wegovy (semaglutide): single GLP-1 receptor agonist
• Mounjaro/Zepbound (tirzepatide): dual GLP-1 + GIP receptor agonist
• Retatrutide: triple GLP-1 + GIP + glucagon receptor agonist

“Better” depends on what is being optimised. For pure weight loss magnitude, retatrutide leads in available trial data. For approved-medication availability, semaglutide and tirzepatide are the current options. For adverse-event profile, the dual and triple agonists trend toward slightly higher GI adverse event rates than semaglutide alone at the top doses.

Retatrutide vs tirzepatide

Both are Eli Lilly products in the incretin-receptor class. Tirzepatide (Mounjaro/Zepbound) is the approved dual GLP-1/GIP agonist; retatrutide is the experimental triple agonist that adds glucagon receptor activation. Mechanistically, the addition of glucagon receptor agonism adds an energy-expenditure component that tirzepatide does not have. Phase 3 head-to-head data is not yet published, but the indirect Phase 2 comparison suggests retatrutide produces larger weight loss at equivalent total dose. Side-effect profiles are similar in shape, with nausea and gastrointestinal symptoms dominating both.

Dosage and administration schedule

Phase 2 trials used retatrutide once weekly by subcutaneous injection at 1 mg, 4 mg, 8 mg, and 12 mg dose levels. Dose escalation from 2 mg starting dose progressed every 4 weeks. The Phase 3 TRIUMPH program uses a similar dose-escalation schedule with maintenance doses of 6 mg, 8 mg, and 12 mg. The 8 mg and 12 mg cohorts show the strongest weight loss but the highest GI adverse event rates; the 4 mg cohort offers a more tolerable profile with still-substantial efficacy.

Side effects and who should not take retatrutide

The Phase 2 adverse-event profile is dominated by gastrointestinal symptoms (nausea, vomiting, diarrhoea, constipation) and discontinuation rates of 6 to 16 percent depending on dose. Other reported events include injection-site reactions, headache, and the increases in heart rate (small but consistent) that the incretin class produces. The glucagon agonism component raises theoretical concerns about insulin sensitivity in non-diabetic populations and about hepatic glucose effects, but the published data does not show clinically meaningful hyperglycemia.

Likely contraindications (still being characterised in late-phase trials) follow the incretin class: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastroparesis, severe diabetic retinopathy, and pregnancy. Patients with type 1 diabetes or uncontrolled type 2 diabetes should not use the compound outside of monitored research protocols.

When will retatrutide be available in Canada?

Retatrutide is not yet approved by Health Canada, the FDA, or any major regulatory body. The Phase 3 TRIUMPH program was initiated in 2022 with key readouts expected through 2026 and 2027. If pivotal-trial data continues to support the Phase 2 efficacy signal, Health Canada and FDA approvals could follow in 2027 or 2028. Until approval, research-grade retatrutide is available in Canada and the United States only as a research chemical under research-use-only labelling.

Cost expectations and clinical trial access

If approved, retatrutide is likely to be priced in the same range as tirzepatide (Zepbound) and semaglutide (Wegovy), which means CAD 400-600 per month at retail. Insurance and PBM coverage will follow the same pattern as the approved obesity medicines. Clinical trial enrollment in the TRIUMPH program is the current legitimate access pathway in Canada; trial sites are listed at clinicaltrials.gov.

Other health conditions beyond weight loss

The Phase 2 retatrutide program also covered type 2 diabetes, NAFLD/NASH, and hypertension. Effects on glycemic control were strong (HbA1c reductions of 1.5 to 2.0 percentage points at top doses), liver-fat reductions were dramatic (80-90 percent), and blood pressure reductions were consistent with the incretin class. Late-phase trials are also evaluating cardiovascular outcomes, which the incretin class is increasingly expected to deliver. The breadth of metabolic effect makes retatrutide an interesting research tool for studying the triple-agonist mechanism across endpoints, not just weight.

Legal status

Retatrutide is not approved as a finished pharmaceutical in any jurisdiction. Research-grade material is legal in Canada and the United States as a research chemical sold under research-use-only labelling. The peptide is not on the World Anti-Doping Agency prohibited list, though athletes should monitor for updates given the metabolic-effect mechanism.

Sourcing for research

Reproducible incretin research depends on the integrity of the input material:

• Batch-specific Certificate of Analysis from an independent third-party laboratory
• HPLC purity confirmation at 98 percent or above, with chromatogram trace
• Mass spectrometry verification of the expected ~4,731 Da molecular weight
• Endotoxin and sterility testing for in vivo or cell-culture work

Reviv Peptides supplies research-grade retatrutide with third-party COA and HPLC purity confirmation. View the Retatrutide product page.

Retatrutide questions

What does retatrutide do to your body and how does it work?

Retatrutide is a triple receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. The downstream effects include appetite suppression, slower gastric emptying, insulin secretion, and increased energy expenditure (the glucagon component). Net result is substantial body weight reduction and improved glycemic control.

Is retatrutide more effective than Ozempic?

On weight loss magnitude, available Phase 2 data places retatrutide ahead (24.2 percent at 12 mg over 48 weeks vs 14.9 percent for semaglutide at 2.4 mg over 68 weeks). For approved-medication availability, semaglutide is the current option; retatrutide is still in Phase 3 trials.

When will retatrutide be available in Canada?

Not yet approved. Phase 3 TRIUMPH program readouts expected 2026-2027. Health Canada approval likely 2027 or 2028 if pivotal data supports the Phase 2 efficacy signal.

Who should not take retatrutide?

Likely contraindications (still being characterised) include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastroparesis, type 1 diabetes, and pregnancy. The compound is not appropriate for unmonitored use outside of clinical trials.

How much weight can someone expect to lose with retatrutide?

Phase 2 data: 8.7 percent at 1 mg, 17.1 percent at 4 mg, 22.8 percent at 8 mg, and 24.2 percent at 12 mg over 48 weeks. Magnitude is dose-dependent and exceeds both semaglutide and tirzepatide at equivalent total exposure.

Key data point: Jastreboff et al. (2023, NEJM) reported that Retatrutide’s triple agonism produced a clinically meaningful separation from dual agonist tirzepatide specifically in hepatic fat fraction — dual agonists reduced liver fat by ~15%, while retatrutide reduced it by ~26% at comparable metabolic timepoints, with the additional benefit attributed to glucagon receptor-driven hepatic lipid oxidation.

Summary

Retatrutide (LY3437943) is the first triple agonist incretin-class peptide to reach late-phase trials, simultaneously engaging GLP-1, GIP, and glucagon receptors. The Phase 2 obesity dataset shows weight loss of 24.2 percent over 48 weeks at the 12 mg dose, the largest reduction reported for any incretin peptide. The mechanism combines appetite suppression (GLP-1), insulin secretion (GIP), and energy expenditure (glucagon agonism). The Phase 3 TRIUMPH program is underway; Health Canada and FDA approval is plausible in 2027 or 2028. Research-grade material is currently available in Canada and the United States as a research chemical under research-use-only labelling.

All products sold by Reviv Peptides are for research and educational purposes only and are not intended for human consumption.